Press Releases

In This Section

Filter Releases
 
Press Releases
Date Title and Summary View
Mar 15, 2017
Company Reiterates FY 2017 Total Net Product Sales Expected to be Between $155 and $165 million Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, March 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of...
Mar 13, 2017
VANCOUVER, British Columbia, March 13, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Wednesday, March 15, 2017 at 8:30...
Mar 8, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 29th Annual ROTH Conference. Chief ...
Mar 7, 2017
VANCOUVER, British Columbia & CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the United States Patent Trial and Appeal Board (PTAB) issued a written de...
Mar 1, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Cowen and Company 37th Annual Healt...
Feb 28, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced today its alliance with the National Organization for Rare Disorders (NORD), R...
Jan 23, 2017
VANCOUVER, British Columbia, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applic...
Jan 9, 2017
- Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance - Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical...
Jan 4, 2017
VANCOUVER, B.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive ...
Dec 22, 2016
- If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies - More than 100 patients are currently treated with metreleptin via a compassionate use program in Europe VANCOUVER, B.C., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biop...
Dec 16, 2016
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (the "Company"), today completed a one-for-five (1:5) reverse split of its common stock (the "Consolidation"). The C...
Dec 16, 2016
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics (NASDAQ:NVLN) (TSX:NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first commercial shipment of JUXTAPID® (lomitapide) to a patient in Japan. In September 2016, JUXTAPID was approved by Japan's Ministry of Health, Labor & Welfar...
Dec 5, 2016
VANCOUVER, British Columbia, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (the "Company"), today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsi...
Dec 5, 2016
-- Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide - CAMBRIDGE, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), today announced that its subsidiary, Aegerion Pharmaceuticals, Inc., has entered...

= add release to Briefcase